WO1996036350B1 - Utilisation d'il-13 pour induire la 15-lipoxygenase - Google Patents
Utilisation d'il-13 pour induire la 15-lipoxygenaseInfo
- Publication number
- WO1996036350B1 WO1996036350B1 PCT/US1996/006779 US9606779W WO9636350B1 WO 1996036350 B1 WO1996036350 B1 WO 1996036350B1 US 9606779 W US9606779 W US 9606779W WO 9636350 B1 WO9636350 B1 WO 9636350B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- activity
- lta
- human
- hydroxylase
- inflammatory condition
- Prior art date
Links
- 102000009515 Arachidonate 15-Lipoxygenase Human genes 0.000 title 1
- 108010048907 Arachidonate 15-Lipoxygenase Proteins 0.000 title 1
- 230000000694 effects Effects 0.000 claims abstract 11
- 230000004968 inflammatory condition Effects 0.000 claims abstract 8
- 230000001939 inductive effect Effects 0.000 claims abstract 4
- 230000015572 biosynthetic process Effects 0.000 claims abstract 3
- 230000004054 inflammatory process Effects 0.000 claims abstract 3
- 206010061218 Inflammation Diseases 0.000 claims abstract 2
- 210000001616 Monocytes Anatomy 0.000 claims abstract 2
- UFPQIRYSPUYQHK-WAQVJNLQSA-N Leukotriene A4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@@H]1O[C@H]1CCCC(O)=O UFPQIRYSPUYQHK-WAQVJNLQSA-N 0.000 claims 7
- 210000004027 cells Anatomy 0.000 claims 7
- 102100009823 ALOX5 Human genes 0.000 claims 6
- 101710036546 ALOX5 Proteins 0.000 claims 6
- 230000037396 body weight Effects 0.000 claims 6
- 230000000754 repressing Effects 0.000 claims 5
- 230000037348 biosynthesis Effects 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 210000002540 Macrophages Anatomy 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000002639 lipoxins Chemical class 0.000 claims 1
- 230000001404 mediated Effects 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 abstract 1
- 230000003110 anti-inflammatory Effects 0.000 abstract 1
- 230000002708 enhancing Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- IXAQOQZEOGMIQS-SSQFXEBMSA-M lipoxin A4(1-) Chemical compound CCCCC[C@H](O)\C=C\C=C/C=C/C=C/[C@@H](O)[C@@H](O)CCCC([O-])=O IXAQOQZEOGMIQS-SSQFXEBMSA-M 0.000 abstract 1
- 230000001717 pathogenic Effects 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 230000002194 synthesizing Effects 0.000 abstract 1
- 230000001225 therapeutic Effects 0.000 abstract 1
Abstract
La présente invention se fonde sur la découverte que l'IL-13 favorise la production de 15-LO chez les monocytes humains. Contrairement à ce qu'on pourrait attendre, l'IL-13 s'avère environ dix fois plus active, sur une base molaire, que l'IL-4 dans la production de 15-LO. L'IL-13 est donc une substance thérapeutique efficace dans le cas d'états inflammatoires réagissant aux produits de l'activité du 15-LO, notamment 15-S-HETE et LXA4. En favorisant des voies endogènes conduisant à la synthèse de molécules anti-inflammatoires endogènes, l'administration d'IL-13 aboutit à l'inhibition des effecteurs terminaux du processus inflammatoire lui-même. La stratégie employée consiste donc à intervenir directement sur des molécules pathogènes spécifiques, par opposition à la méthode actuelle qui consiste à traiter les symptômes de l'inflammation.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU60224/96A AU6022496A (en) | 1995-05-19 | 1996-05-13 | Use of il-13 to induce 15-lipoxygenase |
| EP96917810A EP0831889A4 (fr) | 1995-05-19 | 1996-05-13 | Utilisation d'il-13 pour induire la 15-lipoxygenase |
| JP8534942A JPH11505247A (ja) | 1995-05-19 | 1996-05-13 | １５−リポキシゲナーゼを誘導するためのｉｌ−１３の使用 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/445,311 | 1995-05-19 | ||
| US08/445,311 US5830453A (en) | 1995-05-19 | 1995-05-19 | Use of IL-13 to induce 15-lipoxygenase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1996036350A1 WO1996036350A1 (fr) | 1996-11-21 |
| WO1996036350B1 true WO1996036350B1 (fr) | 1997-01-03 |
Family
ID=23768427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1996/006779 WO1996036350A1 (fr) | 1995-05-19 | 1996-05-13 | Utilisation d'il-13 pour induire la 15-lipoxygenase |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US5830453A (fr) |
| EP (1) | EP0831889A4 (fr) |
| JP (2) | JPH11505247A (fr) |
| AU (1) | AU6022496A (fr) |
| CA (1) | CA2221449A1 (fr) |
| WO (1) | WO1996036350A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6509313B1 (en) | 1996-02-28 | 2003-01-21 | Cornell Research Foundation, Inc. | Stimulation of immune response with low doses of cytokines |
| US6242473B1 (en) * | 1999-01-08 | 2001-06-05 | Maxim Pharmaceuticals, Inc. | Treatment and prevention of reactive oxygen metabolite-mediated cellular damage |
| US6703360B2 (en) | 2000-04-07 | 2004-03-09 | Heska Corporation | Compositions and methods related to canine IgG and canine IL-13 receptors |
| JP4676054B2 (ja) * | 2000-10-16 | 2011-04-27 | 友昭 星野 | 肥満および肥満関連疾病治療薬並びにその評価方法 |
| AU2002320630A1 (en) | 2001-07-17 | 2003-03-03 | University Of Florida | Detecting and treating reproductive tract disorders |
| EP2273419B1 (fr) * | 2002-06-14 | 2012-03-14 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Méthode pour le traitement et la prévention de la colite impliquant IL-13 et des cellules NK-T |
| AU2003221707A1 (en) * | 2002-06-14 | 2003-12-31 | Alcon, Inc. | Topical use of hydroxyeicosatetraenoic acid compounds to treat psoriasis |
| AU2004255564A1 (en) | 2003-06-10 | 2005-01-20 | The J. David Gladstone Institutes | Methods for treating lentivirus infections |
| EP1824886B1 (fr) | 2004-11-17 | 2010-12-22 | Amgen Inc. | Anticorps monoclonaux entierement humains diriges contre l'il-13 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5079261A (en) * | 1989-04-28 | 1992-01-07 | Brigham And Women's Hospital | Use of lipoxin a4 and its derivatives as antagonists for slow-reacting substances of anaphylaxis |
| WO1994004680A1 (fr) * | 1992-08-21 | 1994-03-03 | Schering Corporation | Interleukine-13 humaine |
-
1995
- 1995-05-19 US US08/445,311 patent/US5830453A/en not_active Expired - Fee Related
-
1996
- 1996-05-13 CA CA002221449A patent/CA2221449A1/fr not_active Abandoned
- 1996-05-13 AU AU60224/96A patent/AU6022496A/en not_active Abandoned
- 1996-05-13 EP EP96917810A patent/EP0831889A4/fr not_active Withdrawn
- 1996-05-13 WO PCT/US1996/006779 patent/WO1996036350A1/fr not_active Application Discontinuation
- 1996-05-13 JP JP8534942A patent/JPH11505247A/ja not_active Ceased
-
2005
- 2005-02-01 JP JP2005025745A patent/JP2005120111A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Loria et al. | Regulation of the immune response by dehydroepiandrosterone and its metabolites | |
| US5874444A (en) | Poly (ADP-ribose) polymerase inhibitors to treat diseases associated with cellular senescence | |
| EP1310249B1 (fr) | Utilisation d'acides gras polyinsaturés pour la prévention primaire d'accidents cardio-vasculaires | |
| JP3062974B2 (ja) | 睡眠障害治療剤 | |
| CA2120424A1 (fr) | Composition anti-osteopathique | |
| US4870101A (en) | Method of inhibiting interleukin-1 release | |
| WO1994023722A1 (fr) | Activite de tamponnage de l'hydrocortisone | |
| AU5257793A (en) | Compositions of L-DOPA esters | |
| CA2352544A1 (fr) | Utilisation de derives n-alkyle a chaine longue de desoxynojirimycine pour l'elaboration d'un medicament permettant de traiter les maladies liees au stockage des glycolipides | |
| MXPA01007662A (es) | Epa de etilo altamente purificado y otros derivados de epa para desordenes psiquiatricos y neurologicos. | |
| Pai et al. | Potential of ozonated sesame oil to augment wound healing in rats | |
| RO108220B1 (ro) | Preparate farmaceutice,pentru combaterea carceilor musculari si procedeu de obtinere a acestora | |
| WO1996036350B1 (fr) | Utilisation d'il-13 pour induire la 15-lipoxygenase | |
| EP1165066A1 (fr) | Utilisation de composes de lipoxine afin d'inhiber la reponse de neutrophile induite par tnf-alpha | |
| Saitou et al. | Slow wave sleep-inducing effects of first generation H1-antagonists | |
| US5478566A (en) | Stimulation of cytokine production | |
| Takahashi et al. | Inhibition of tumor necrosis factor prevents warming-induced sleep responses in rabbits | |
| AU601554B2 (en) | Method of inhibiting interleukin-1 release | |
| US6696498B2 (en) | 2-cyclopenten-1-one and its derivatives as inhibitors of the NF-kB factor | |
| Banner et al. | Anti-inflammatory effects of theophylline and selective phosphodiesterase inhibitors | |
| US5854271A (en) | Effective method for the amelioration and prevention of tissue and cellular damage | |
| US4459310A (en) | Method for cholesterol lowering | |
| US20040028756A1 (en) | Platelet-activated factor antagonists as analgesic, anti-inflammatory, uterine contraction inhibiting, and anti-tumor agents | |
| WO1996030016A3 (fr) | Formulations de ridogrel a petites doses et leur utilisation dans le traitement de maladies intestinales inflammatoires | |
| GB2196850A (en) | Pharmaceutical compositions containing 2-(phenyl)benzofuran derivatives |